drugset / Trial / NCT01638923

Study of a 4-phasic Oral Contraceptive for the Treatment of Heavy Menstrual Bleeding

NCT01638923

Phase 3 Completed 339 enrolled Bayer
RandomizedParallel-groupQuadruple-blindTreatment

Summary

To evaluate efficacy and safety of a combined oral contraceptive of estradiol valerate and dienogest in the treatment of heavy menstrual bleeding

Timeline

Start
2012-06
Primary completion
2015-06
Completion
2015-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Dienogest Small molecule 3 mg Oral
Subject estradiol valerate Unknown 2 mg Oral

Indications